Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN 

Arrowhead’s bid to become a large-cap biotech

After 20 years of platform building and resets,  Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built a pipeline and set of enabling technologies that could enable a steep period of value creation based on RNAi.

The team then analyzes the $2 billion deal between Synnovation LLC and Novartis AG (SIX:NOVN; NYSE:NVS) for a pan-mutant-selective PI3Kα inhibitor.

The analysts also assess where AI is integrating into the biotech venture funnel and provide insights into ultra-rare disease advocacy, FDA’s search for a successor to CBER Director Vinay Prasad, and the Trump administration’s most-favored nation (MFN) drug pricing policy.